Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early-stage antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline please visit www.acurxpharma.com.
Company profile
Ticker
ACXP
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Acurx Pharmaceuticals, LLC
SEC CIK
ACXP stock data
Latest filings (excl ownership)
RW
Registration withdrawal request
17 Apr 24
FWP
Free writing prospectus
2 Apr 24
S-1/A
IPO registration (amended)
29 Mar 24
8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
18 Mar 24
S-1
IPO registration
18 Mar 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
14 Nov 23
Transcripts
ACXP
Earnings call transcript
2023 Q4
18 Mar 24
ACXP
Earnings call transcript
2023 Q3
14 Nov 23
ACXP
Earnings call transcript
2023 Q2
14 Aug 23
ACXP
Earnings call transcript
2023 Q1
12 May 23
ACXP
Earnings call transcript
2022 Q4
16 Mar 23
ACXP
Earnings call transcript
2022 Q3
14 Nov 22
ACXP
Earnings call transcript
2022 Q2
16 Aug 22
ACXP
Earnings call transcript
2022 Q1
11 May 22
ACXP
Earnings call transcript
2021 Q4
17 Mar 22
ACXP
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.05 mm | 7.05 mm | 7.05 mm | 7.05 mm | 7.05 mm | 7.05 mm |
Cash burn (monthly) | 697.84 k | 296.25 k | 1.04 mm | 1.06 mm | 697.84 k | 591.56 k |
Cash used (since last report) | 4.80 mm | 2.04 mm | 7.14 mm | 7.29 mm | 4.80 mm | 4.07 mm |
Cash remaining | 2.25 mm | 5.01 mm | -89.71 k | -240.90 k | 2.25 mm | 2.98 mm |
Runway (months of cash) | 3.2 | 16.9 | -0.1 | -0.2 | 3.2 | 5.0 |
Institutional ownership, Q2 2023
9.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.89 bn |
Total shares | 1.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 1.18 mm | $3.13 bn |
Vanguard | 121.04 k | $320.77 mm |
Geode Capital Management | 77.28 k | $204.80 mm |
Advisor | 22.00 k | $58.30 mm |
BLK Blackrock | 18.88 k | $50.02 mm |
Millennium Management | 17.31 k | $45.87 mm |
One68 Global Capital | 13.04 k | $34.57 mm |
Tocqueville Asset Management | 10.10 k | $26.77 mm |
Tower Research Capital | 4.45 k | $11.78 mm |
RY Royal Bank Of Canada | 121.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Feb 24 | David P Luci | Stock Option Common Stock | Grant | Acquire A | No | No | 3.15 | 250,000 | 787.50 k | 250,000 |
23 Feb 24 | Robert G. Shawah | Stock Option Common Stock | Grant | Acquire A | No | No | 3.15 | 145,000 | 456.75 k | 145,000 |
23 Feb 24 | Robert J Deluccia | Stock Option Common Stock | Grant | Acquire A | No | No | 3.15 | 250,000 | 787.50 k | 250,000 |
19 Jan 24 | Carl Sailer | Common Stock | Option exercise | Acquire M | No | No | 3.55 | 19,737 | 70.07 k | 112,552 |
19 Jan 24 | Carl Sailer | Warrants for Common Stock Common Stock | Option exercise | Dispose M | No | No | 3.55 | 19,737 | 70.07 k | 0 |
3 Jan 24 | David P Luci | Common Stock | Option exercise | Acquire M | No | No | 3.55 | 19,737 | 70.07 k | 1,048,197 |
3 Jan 24 | David P Luci | Warrants for Common Stock Common Stock | Option exercise | Dispose M | No | No | 3.55 | 19,737 | 70.07 k | 0 |
News
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
18 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Mar 24
HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $12
19 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
18 Mar 24
Earnings Scheduled For March 18, 2024
18 Mar 24
Press releases
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
25 Apr 24
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
4 Mar 24
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
29 Feb 24
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
27 Feb 24
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
23 Feb 24